Pinz Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Pinz Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-170	Closed	-$2K	–	298
2021 Q4	$2K	Buy	+170	New	+$1.67K	﹤0.01%	348

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

Pinz Capital Management's EUCR Position: Q1 2022 in Review

Pinz Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q1 2022, closing a stake of 170 shares — an estimated $2K sold.

Pinz Capital Management first reported a position in EUCR in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q1 2022.

Pinz Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Pinz Capital Management sold 170 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q1 2022, an estimated $2K.
Pinz Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 1 quarter.
Pinz Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $2K in Q4 2021.
39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2022.

Based on Pinz Capital Management's 13F filing for Q1 2022, filed 16 May 2022.